Treace Medical Concepts (TMCI) executive has 1,797 shares withheld for taxes

Rhea-AI Filing Summary

Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported tax-withholding dispositions of company stock. On March 8 and March 10, 2026, a total of 1,797 shares of Common Stock were withheld to satisfy tax obligations, not sold on the open market.

After the March 10 transaction, he directly holds 704,677 shares of Common Stock, which includes 509,648 restricted stock units.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Scanlan Sean F.

Role Chief Innovation Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,396	$0.00	--
Tax Withholding	Common Stock	401	$0.00	--

Holdings After Transaction: Common Stock — 704,677 shares (Direct)

Footnotes (1)

1. Includes 509,648 restricted stock units. Includes 503,917 restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scanlan Sean F.

(Last) (First) (Middle)

C/O TREACE MEDICAL CONCEPTS, INC.

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FL 32081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Innovation Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/08/2026		F		401	D	$0	706,073(1)	D
Common Stock	03/10/2026		F		1,396	D	$0	704,677(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 509,648 restricted stock units.

2. Includes 503,917 restricted stock units.

	/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TMCI executive Sean F. Scanlan report?

Sean F. Scanlan reported tax-withholding dispositions of Treace Medical Concepts stock. On March 8 and March 10, 2026, a total of 1,797 Common Stock shares were withheld to cover tax liabilities rather than sold in open-market trades.

How many TMCI shares were withheld for Sean F. Scanlan’s taxes?

A total of 1,797 Treace Medical Concepts Common Stock shares were withheld. The Form 4 shows 401 shares on March 8, 2026, and 1,396 shares on March 10, 2026, all applied to satisfy tax obligations on equity compensation.

Were Sean F. Scanlan’s TMCI transactions open-market sales or tax withholding?

The transactions were tax-withholding dispositions, not open-market sales. Code F on the Form 4 indicates shares were delivered back to the issuer to pay exercise price or tax liabilities tied to equity awards.

What is Sean F. Scanlan’s TMCI share ownership after these transactions?

After the March 10, 2026 tax-withholding transaction, Sean F. Scanlan directly owns 704,677 Treace Medical Concepts Common Stock shares. This total includes 509,648 restricted stock units that remain subject to vesting or other award conditions.

What role does Sean F. Scanlan hold at Treace Medical Concepts (TMCI)?

Sean F. Scanlan serves as Chief Innovation Officer at Treace Medical Concepts. His Form 4 filing reflects equity-based compensation activity, including tax-withholding dispositions of Common Stock tied to restricted stock units and related awards.

How many TMCI restricted stock units are included in Scanlan’s holdings?

Scanlan’s reported holdings after the latest transaction include 509,648 restricted stock units. These RSUs form a substantial portion of his 704,677 total direct Common Stock holdings disclosed in the March 10, 2026 Form 4 filing.